OA-48 Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed multiple myeloma (IKEMA): final overall survival analysis

Journal article

Peer reviewed

Kwee Yong, Thomas Martin, Meletios Dimopoulos, Joseph Mikhael, Marcelo Capra, Thierry Facon, Roman Hájek, Ivan Špička, Ross Baker, Kihyun Kim, …

Clinical lymphoma, myeloma and leukemia, Vol.23, pp.S30-S31

2023

Details

Title: OA-48 Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed multiple myeloma (IKEMA): final overall survival analysis
Authors/Creators: Kwee Yong - University College Hospital
Thomas Martin - University of California, San Francisco
Meletios Dimopoulos
Joseph Mikhael - Translational Genomics Research Institute
Marcelo Capra - Hospital Mãe de Deus
Thierry Facon - Lille’s Cardiology Hospital
Roman Hájek - University of Ostrava
Ivan Špička - Charles University
Ross Baker
Kihyun Kim - Sungkyunkwan University
Gracia Martinez - Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
Chang-Ki Min - Catholic University of Korea
Ludek Pour - University Hospital Brno
Xavier Leleu - Inserm
Albert Oriol - Institut Català d'Oncologia
Youngil Koh - Seoul National University Hospital
Kenshi Suzuki - Japanese Red Cross Medical Center
France Casca - Arysta LifeScience (France)
Sandrine Macé - Sanofi (France)
Philippe Moreau
Marie-Laure Risse
Publication Details: Clinical lymphoma, myeloma and leukemia, Vol.23, pp.S30-S31
Publisher: Elsevier Ltd.
Identifiers: 991005616269607891
Murdoch Affiliation: Centre for Molecular Medicine and Innovative Therapeutics; Murdoch University
Language: English
Resource Type: Journal article
Note: Part of special issue: The Abstract from International Myeloma Society 20th Annual Meeting and Exposition

64 Record Views